#2-03E. Early Intervention with Sotatercept in PAH: The HYPERION Trial Insights (NEJM, 2025)

How can we optimize outcomes for newly diagnosed patients with pulmonary arterial hypertension (PAH)? This episode delves into the HYPERION trial, a phase 3 study investigating the efficacy of sotatercept, a novel activin-signaling inhibitor, when added to background therapy in adult PAH patients within their first year of diagnosis. The study demonstrated that sotatercept significantly reduced the risk of clinical worsening compared to placebo. The most critical clinical finding is that sotatercept lowered the risk of clinical worsening by 76% (hazard ratio, 0.24), highlighting its substantial benefit in an early-course PAH population. This finding is particularly relevant for clinicians as it provides strong evidence for initiating this novel therapy early to potentially alter the disease trajectory. However, it is important to note that the trial was terminated prematurely, which limits the assessment of long-term safety and efficacy. Join us as we explore the implications of these findings for early PAH management.

Citation: McLaughlin, V.V., et al. Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis. New England Journal of Medicine. 2025. DOI: 10.1056/NEJMoa2508170

Disclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original article for details.